Increased expression of periostin in vitreous and fibrovascular membranes obtained from patients with proliferative diabetic retinopathy

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 8, 2011, Pages 5670-5678

  Yoshida, Shigeo ^a   Ishikawa, Keijiro ^a   Asato, Ryo ^a,b   Arima, Mitsuru ^a   Sassa, Yukio ^a,b   Yoshida, Ayako ^a   Yoshikawa, Hiroshi ^a   Narukawa, Keisuke ^c   Obika, Satoshi ^c   Ono, Junya ^d   Ohta, Shoichiro ^e   Izuhara, Kenji ^e   Kono, Toshihiro ^b   Ishibashi, Tatsuro ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Fukuoka University Chikushi Hospital   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d SHINO TEST CORPORATION   (Japan)

^e SAGA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; FIBROBLAST GROWTH FACTOR 2; MESSENGER RNA; TRANSCRIPTION FACTOR RUNX2; VASCULOTROPIN; ACTIN; CELL ADHESION MOLECULE; POSTN PROTEIN, HUMAN;

ADULT; ARTICLE; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; DIABETIC RETINOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIRETINAL MEMBRANE; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA MACULA HOLE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VITRECTOMY; VITREOUS BODY; ALTERNATIVE RNA SPLICING; CELL CULTURE; CELL MOTION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PIGMENT EPITHELIUM; UPREGULATION;

ACTINS; ALTERNATIVE SPLICING; CELL ADHESION; CELL ADHESION MOLECULES; CELL MOVEMENT; CELLS, CULTURED; DIABETIC RETINOPATHY; FEMALE; HUMANS; MALE; MIDDLE AGED; OLIGORIBONUCLEOTIDES, ANTISENSE; RETINAL PIGMENT EPITHELIUM; UP-REGULATION; VITRECTOMY; VITREOUS BODY;

EID: 80053295748     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6625     Document Type: Article

References (53)

1. Dorrell M, Uusitalo-Jarvinen H, Aguilar E, Friedlander M. Ocular neovascularization: basic mechanisms and therapeutic advances. Surv Ophthalmol. 2007;52(suppl 1):S3-S19.
2. Yoshida A, Yoshida S, Ishibashi T, Inomata H. Intraocular neovascularization. Histol Histopathol. 1999;14:1287-1294.
3. Hiscott P, Wong D, Grierson I. Challenges in ophthalmic pathology: the vitreoretinal membrane biopsy. Eye. 2000;14(pt
4. Snead DR, James S, Snead MP. Pathological changes in the vitreoretinal junction, 1: epiretinal membrane formation. Eye. 2008;22: 1310-1317.
5. Tao Y, Lu Q, Jiang YR, et al. Apelin in plasma and vitreous and in fibrovascular retinal membranes of patients with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 2010;51:4237-4242.
6. Yoshida A, Yoshida S, Khalil AK, Ishibashi T, Inomata H. Role of NF-kappaB-mediated interleukin-8 expression in intraocular neovascularization. Invest Ophthalmol Vis Sci. 1998;39:1097-1106.
7. Mitamura Y, Harada T, Harada C, et al. NF-kappaB in epiretinal membranes after human diabetic retinopathy. Diabetologia. 2003;46:699-703.
8. Mitamura Y, Okumura A, Harada C, et al. Activator protein-1 in epiretinal membranes of patients with proliferative diabetic retinopathy. Diabetologia. 2006;49:209-211.
9. Mitamura Y, Takeuchi S, Matsuda A, Tagawa Y, Mizue Y, Nishihira J. Monocyte chemotactic protein-1 in the vitreous of patients with proliferative diabetic retinopathy. Ophthalmologica. 2001;215: 415-418.
10. Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med. 2005;353:782-792.
11. Yamaji Y, Yoshida S, Ishikawa K, et al. TEM7 (PLXDC1) in neovascular endothelial cells of fibrovascular membranes from patients with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 2008;49:3151-3157.
12. Yoshida S, Ishikawa K, Matsumoto T, Yoshida A, Ishibashi T, Kono T. Reduced concentrations of angiogenesis-related factors in vitreous after vitrectomy in patients with proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010;248:799-804.
13. Kociok N, Joussen AM. Varied expression of functionally important genes of RPE and choroid in the macula and in the periphery of normal human eyes. Graefes Arch Clin Exp Ophthalmol. 2007;245:101-113.
14. Ishikawa K, Yoshida S, Kadota K, et al. Gene expression profile of hyperoxic and hypoxic retinas in a mouse model of oxygeninduced retinopathy. Invest Ophthalmol Vis Sci. 2010;51:4307-4319.
15. Yoshida S, Ogura A, Ishikawa K, et al. Gene expression profile of fibrovascular membranes from patients with proliferative diabetic retinopathy. Br J Ophthalmol. 2010;94:795-801.
16. Takada M, Ban Y, Yamamoto G, et al. Periostin, discovered by nano-flow liquid chromatography and mass spectrometry, is a novel marker of diabetic retinopathy. Biochem Biophys Res Commun. 2010;399:221-226.
17. Takeshita S, Kikuno R, Tezuka K, Amann E. Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem J. 1993;294(pt
18. Horiuchi K, Amizuka N, Takeshita S, et al. Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. J Bone Miner Res. 1999;14:1239-1249.
19. Kim CJ, Isono T, Tambe Y, et al. Role of alternative splicing of periostin in human bladder carcinogenesis. Int J Oncol. 2008;32: 161-169.
20. Kanno A, Satoh K, Masamune A, et al. Periostin, secreted from stromal cells, has biphasic effect on cell migration and correlates with the epithelial to mesenchymal transition of human pancreatic cancer cells. Int J Cancer. 2008;122:2707-2718.
21. Riener MO, Fritzsche FR, Soll C, et al. Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas. Histopathology. 56:600-606.
22. Bao S, Ouyang G, Bai X, et al. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell. 2004;5:329-339.
23. Kudo Y, Ogawa I, Kitajima S, et al. Periostin promotes invasion and anchorage-independent growth in the metastatic process of head and neck cancer. Cancer Res. 2006;66:6928-6935.
24. Hakuno D, Kimura N, Yoshioka M, et al. Periostin advances atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis and MMP production in humans and rodents. J Clin Invest. 2010;120:2292-2306.
25. Takayama G, Arima K, Kanaji T, et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol. 2006;118:98-104.
26. Oku E, Kanaji T, Takata Y, et al. Periostin and bone marrow fibrosis. Int J Hematol. 2008;88:57-63.
27. Obika S, Nanbu D, Hari Y, et al. Synthesis of 2′-O,4′-C-methyleneuridine and-cytidine. Novel bicyclic nucleosides having a fixed C3′-endo sugar puckering. Tetrahedron Lett. 1997;38:8735-8738.
28. Koshkin A, Sing S, Nielsen P, et al. LNA (locked nucleic acids): synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron. 1998;54:3607-3630.
29. Yoshida S, Ono M, Shono T, et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol. 1997;17:4015-4023.
30. Yoshida S, Yamaji Y, Yoshida A, et al. Novel triple missense mutations of GUCY2D gene in Japanese family with cone-rod dystrophy: possible use of genotyping microarray. Mol Vis. 2006;12:1558-1564.
31. Yoshida S, Yoshida A, Nakao S, et al. Lattice corneal dystrophy type I without typical lattice lines: role of mutational analysis. Am J Ophthalmol. 2004;137:586-588.
32. Yoshida S, Yamaji Y, Yoshida A, Noda Y, Kumano Y, Ishibashi T. Rapid genotyping for most common TGFBI mutations with realtime polymerase chain reaction. Hum Genet. 2005;116:518-524.
33. Yoshida S, Yamaji Y, Yoshida A, Ikeda Y, Yamamoto K, Ishibashi T. Rapid detection of SAG 926delA mutation using real-time polymerase chain reaction. Mol Vis. 2006;12:1552-1557.
34. Yoshida S, Yamaji Y, Kuwahara R, et al. Novel mutation in exon 2 of COL2A1 gene in Japanese family with Stickler Syndrome type I. Eye. 2006;20:743-745.
35. Yoshida S, Kumano Y, Yoshida A, et al. Two brothers with gelatinous drop-like dystrophy at different stages of the disease: role of mutational analysis. Am J Ophthalmol. 2002;133:830-832.
36. Yoshida S, Kumano Y, Yoshida A, et al. An analysis of BIGH3 mutations in patients with corneal dystrophies in the Kyushu district of Japan. Jpn J Ophthalmol. 2002;46:469-471.
37. Yoshida S, Honda M, Yoshida A, et al. Novel mutation in ABCC6 gene in a Japanese pedigree with pseudoxanthoma elasticum and retinitis pigmentosa. Eye. 2005;19:215-217.
38. Yoshida S, Arita R, Yoshida A, et al. Novel mutation in FZD4 gene in a Japanese pedigree with familial exudative vitreoretinopathy. Am J Ophthalmol. 2004;138:670-671.
39. Yoshida S, Yoshida A, Ishibashi T, Kumano Y, Matsui T. Presence of vitronectin in neovascularized cornea of patient with gelatinous drop-like dystrophy. Br J Ophthalmol. 2003;87:368-369.
40. Yoshida A, Yoshida S, Hata Y, Khalil AK, Ishibashi T, Inomata H. The role of NF-kappaB in retinal neovascularization in the rat: possible involvement of cytokine-induced neutrophil chemoattractant (CINC), a member of the interleukin-8 family. J Histochem Cytochem. 1998;46:429-436.
41. Yoshida A, Kawano Y, Kato K, et al. Apoptosis in perforated cornea of a patient with graft-versus-host disease. Can J Ophthalmol. 2006;41:472-475.
42. Yoshida S, Yoshida A, Matsui H, Takada Y, Ishibashi T. Involvement of macrophage chemotactic protein-1 and interleukin-1beta during inflammatory but not basic fibroblast growth factor-dependent neovascularization in the mouse cornea. Lab Invest. 2003;83:927-938.
43. Yoshida S, Yoshida A, Ishibashi T, Elner SG, Elner VM. Role of MCP-1 and MIP-1alpha in retinal neovascularization during postischemic inflammation in a mouse model of retinal neovascularization. J Leukoc Biol. 2003;73:137-144.
44. Hoersch S, Andrade-Navarro MA. Periostin shows increased evolutionary plasticity in its alternatively spliced region. BMC Evol Biol. 2010;10:30.
45. Shimazaki M, Kudo A. Impaired capsule formation of tumors in periostin-null mice. Biochem Biophys Res Commun. 2008;367: 736-742.
46. Shao R, Bao S, Bai X, et al. Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through upregulation of vascular endothelial growth factor receptor 2 expression. Mol Cell Biol. 2004;24:3992-4003.
47. Mikalsen B, Fosby B, Wang J, et al. Genome-wide transcription profile of endothelial cells after cardiac transplantation in the rat. Am J Transplant. 2010;10:1534-1544.
48. Yan W, Shao R. Transduction of a mesenchyme-specific gene periostin into 293T cells induces cell invasive activity through epithelial-mesenchymal transformation. J Biol Chem. 2006;281: 19700-19708.
49. Huang ZL, Lin KH, Lee YC, Sheu MM, Tsai RK. Acute vision loss after intravitreal injection of bevacizumab (Avastin) associated with ocular ischemic syndrome. Ophthalmologica. 2010;224: 86-89.
50. von Hanno T, Kinge B, Fossen K. Retinal artery occlusion following intravitreal anti-VEGF therapy. Acta Ophthalmol. 2010;88:263-266.
51. Gerhardinger C, Brown LF, Roy S, Mizutani M, Zucker CL, Lorenzi M. Expression of vascular endothelial growth factor in the human retina and in nonproliferative diabetic retinopathy. Am J Pathol. 1998;152:1453-1462.
52. Kim I, Ryan AM, Rohan R, et al. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci. 1999;40:2115-2121.
53. Robinson GS, Ju M, Shih SC, et al. Nonvascular role for VEGF: VEGFR-1, 2 activity is critical for neural retinal development. FASEB J. 2001;15:1215-1217.